


FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Attach several sheets if necessary)	Docket Number: 3955.124USU1	Application Number: 10/607,890
	Applicant: CARTER et al.	
	Filing Date: 27 June 2003	Group Art Unit: 1614



U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
62	AU-B-57853/80	6 Nov. 1980	Australia				
6.	WO 91/10743	25 July 1991	WIPO				
6	WO 00/61153	19 Oct. 2000	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
6		CHAM. "Solasodine glycosides as anti-cancer agents: pre-clinical and clinical studies". <i>Asia Pacific Journal of Pharmacology</i> , Vol. 9, pp. 113-118 (1994).
8		GHOSH et al. "Antifilarian effect of solamargine isolated from <i>Solanum khasianum</i> ". <i>Int. Journal Pharmacog.</i> , Vol. 32, No. 2, pp. 184-190 (1994).
6		CHAM et al. "Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides". <i>Cancer Letters</i> , Vol. 59, pp. 183-192 (1991).
6		DAUNTER et al. "Solasodine glycosides. In vitro preferential cytotoxicity for human cancer cells". <i>Cancer Letters</i> , Vol. 55, pp. 209-220 (1990).

23552

PATENT TRADEMARK OFFICE

EXAMINER	<i>G. Peller</i>	DATE CONSIDERED	<i>7/21/07</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			